相关实验视频

Updated: Mar 6, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

伊梅格林在多发性骨髓瘤中通过影响能量代谢和降低IL-16表达的调节来发挥抗瘤活性

Jifeng Jiang¹, Liang Ren², Yifeng Sun³

¹Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China.

Cancer medicine

|March 4, 2026

概括

伊米格林 (IME) 通过阻止细胞循环和改变能量代谢来抑制多发性骨髓瘤 (MM) 细胞生长. 这种新型抗糖尿病药物在MM治疗中具有向IL-16的潜力.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
代谢过程中的代谢.

背景情况:

伊梅格林 (IME) 是一种口服的抗糖尿病药物,具有抗瘤特性.
它对多发性骨髓瘤 (MM) 细胞的影响需要进一步研究.

研究的目的:

为了研究imeglimin的抗MM作用.
阐明伊梅格林对MM细胞作用的潜在机制.

主要方法:

使用MM细胞系和异种移植模型进行体外和体内研究.
海马代谢分析和RNA测序.
单细胞转录组分析以评估IL-16的作用.

主要成果:

伊梅格林胺通过G1/G0细胞周期停止抑制了MM细胞增殖和瘤生长.
IME抑制了氧化酸化,增强了糖解,并减少了IL-16 mRNA的表达.
抗MM效应的部分介导是乳酸的增加和IL-16.6的减少.

结论:

伊梅格林明显示出作为MM的新疗法潜在的潜力.
向IL-16和能量代谢是使用imeglimin治疗MM的有希望的策略.

关键词:

在IL-16中,我们可以看到IL-16.能量代谢能量代谢它们是非常清晰的.多发性骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...